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INTRODUCTION
The prevalence of acute and chronic heart failure is increasing despite improvement in medical, interventional and surgical treatment modalities. Since the first human heart transplantation was performed in 1967, the number of heart transplantations has increased remarkably worldwide, which was contributed by advancement in understanding immunology and rejection, pharmaceutical development and clinical management of the donors and recipients. Donor shortage is the major factor limiting the transplantation rate nowadays. Heart transplantation was the only option for refractory end stage heart failure to allow durable survival, until recently. However, technical advancement of left ventricular assist device (LVAD) made its application feasible in daily practice and improved survival comparable to transplantation and emerged as another valuable option for long term cardiac assist in transplant ineligible patients.
CURRENT STATUS OF HEART TRANSPLANTATION WORLDWIDE
Transplantation rate has been increased since 1980s until its peak in 1990s, when it became more stable in recent days. More Heart transplantation is the last treatment option in refractory end stage heart failure, which can prolong survival. The number of heart transplantations has increased and the survival rate has improved during the last few decades which was contributed by advanced understanding of immunologic mechanism of rejection, pharmaceutical development and clinical management of donors and recipients. However, only a fraction of patients can be offered to transplantation due to shortage of donor heart and many patients suffer high mortality while waiting. Meanwhile, technical advancement of mechanical assist device in recent years enabled long term implantable left ventricular assist devices (LVAD) to bridge the patients with high mortality in the waiting list to transplantation and to assist as a long term destination therapy for patients who are not eligible for transplantation. Development of solid phase assay increased the sensitivity and the specificity of detection of anti-human leukocyte antigen (HLA) antibodies in the recipient. It enabled identifying unacceptable HLA antigens, acquire calculated Panel Reactive Antibodies and perform virtual cross match that can enhance the efficacy of donor allocation system to decrease the waiting time, obviate prospective cross match to decrease ischemic time and to assess the risk of rejection in presensitized patients. Antibody mediated rejection is a challenging entity in diagnosis and management. However, standardized classification of histology and immunology of endomyocardial biopsies was made recently and immunotherapy is moving toward targeted therapies directed at antibody production and function. This review focuses on those major changes in the heart transplantation field in the last decade.
103, 299 cases of pediatric and adult heart transplants which were undergone between 1982 and 2011 in the world, 1-year survival rate was 81%, 5-year survival rate 69%, median survival rate 11
years for all the patients and 13 years for those surviving after the first year of transplantation according to ISHLT report ( Fig. 2A ) [1] . It is clear that heart transplantation is now a valuable treatment option for refractory end stage heart failure.
Survival rate improved continuously over the last 3 decades which was mostly contributed by reduction of mortality in the first-trans- Regarding underlying etiology of heart failure, dilated cardiomyopathy and ischemic cardiomyopathy are the two most common causes of transplantation which showed favorable prognosis compared to congenital heart disease and retransplantation in early survival. However, congenital heart disease is not a risk factor [1] , (B) Number of heart transplantation in Korea (from presentation at APCHF 2013), (C) Number of LVAD in US from 5th IM-TERMACS report [14] .
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Heart transplantation can be considered in the advanced heart failure patients who are in critical condition with no other long term option or in chronically refractory to conventional treatment and inotrope dependent patients or in ambulatory but frequently hospitalized patients due to decompensated heart failure. To better evaluate the ambulatory heart failure patients, VO2max is an extremely valuable parameter which can assess cardiac output indirectly and noninvasively in response to exercise. Moreover, other risk factors should be considered or avoided to achieve the best result possible which are comorbidities such as advanced DM, irre- 
HEART TRANSPLANTATION IN KOREA
In Korea, a total of 903 heart transplantations were done by December 2013 since its first performance in 1992. It increased steadily from less than 30 cases a year by the mid 2000s to more than 100 cases annually since 2011 (Fig. 1B) . However, the waiting list for transplantation increased sharply compared to the transplantation 2B ). Cause of death was similar to ISHLT data, of which the most common cause was graft failure in the first month, infection was the most common cause after the first month during the first year, rejection peaked in the first to third post transplantion year and malignancy and CAV became the major cause of death thereafter [6] [7] [8] .
CURRENT STATUS OF LEFT VENTRICULAR ASSIST DEVICE
REMATCH trial in 2001 was the first study that showed long term survival benefit of the first generation pulsatile pump LVAD (Heart Mate XVE ® , Thoratec Co, USA) over medical treatment in refractory heart failure who were ineligible for transplantation) [9] . (Fig. 1C ) [14] . The number of BTT also increased and improved the survival rate of transplant candidates in waiting list [15] . On the other hand, there is concern that increase of VAD complications which accompany increase in BTT such as systemic or local infection, bleeding from coagulopathy, throm bembolic events, pump failure and presensitization of candidates, would render the candidates to more prolonged waiting time and complicated transplantation. However, after the debate over the post-transplantation survival with BTT [16] , the short and long term survival rate in durable continuous flow LVAD era seem to be comparable to that of heart transplantation without LVAD except for the transplantations with few complications such as device infection [17, 18] . anti-HLA Ags in the donor pool, thus allowing the prediction of the probability of finding a donor heart without unacceptable Ag [28] . Virtual crossmatch compares the HLA Ag of donor and HLA Ab of recipient virtually before transplantation, which can avoid prospective crossmatching and save time to allow an acceptable ischemic time until the donor heart arrives; thus enabling an increase in the available donor pool [29] . Defining the cutoff of unacceptable Ag is upto each center, which is generally more than 5,000-10,000 MFI (Mean Florescence Intensity); but it also depends on the ability and willingness of the center to deal with high risk transplantation (Fig. 3 ).
Desensitization
Surprisingly, there are few observational studies, but no rando- 2.2%) [31] , which showed benefit of desensitization therapy.
PP aims to remove preformed antibodies, but it is usually com- Rituximab is a chimeric monoclonal Ab against B cell receptor CD20, which is primarily used in B cell neoplasm. It has limited experience in heart transplantation but a small series coming from renal transplantation was shown effectiveness for desensitization and treatment of AMR along with IVIg [32, 33] .
Bortezomib is a 26S proteasome inhibitor approved in multiple myeloma and lymphoma which decreases production of alloantibodies by plasma cells and induces cell apoptosis. It has been reported to be effective in a few cases of desensitization and treatment of AMR in heart and kidney co-transplantation [34, 35] . 
POST TRANSPLANTATION MONITORING AND IMMUNOSUPPRESSIVE THERAPY

Induction therapy
Immune and clinical monitoring after transplantation
Endomyocardial biopsy (EMB), therapeutic drug monitoring (TDM), serology for donor specific Abs (DSA), and echocardiography are all done periodically for surveillance of graft function and early sign of rejection, especially in the first year of transplantation; however, no one method can replace all the others.
EMB is the sine qua non essential tool for the diagnosis of acute and chronic rejection at present since the diagnostic criteria is based on pathologic findings. However, it is an invasive procedure which has low but definite side effects and has the probability of missing the patch distribution of rejection. The pathologic findings appear in the late stage, so there is much effort made to replace or reduce EMB with noninvasive sensitive and specific tests. In the CARGO study, genetic markers of moderate/severe rejection were derived and validated with microarray technology. It showed good agreement with ISHLT≥3A cellular rejection and was able to avoid EMB in the low rejection risk population after 6 months to 1 year of transplantation [38, 39] .
Graft systolic function should be monitored through regular echocardiography along with EMB and serum DSA, but as systol- ic dysfunction is a late manifestation of rejection, clinical suspicion and immunopathologic findings are important for early diagnosis of rejection [40] .
Maintenance immunotherapy
The cornerstone of longterm success of transplantation is the management of immunosuppressive drugs which are to prevent or to treat rejection and minimize complication.
Introduction of cyclosporine in the early 1980s was a milestone in transplantation history which decreased rejection related mortality remarkably compared to the time prior to cyclosporine. Introduction of tacrolimus (FK 506) in the 1990s seems to have superior prevention in acute rejection with comparable risk of renal dysfunction and infection with cyclosporine, although there was no difference in 1 year survival rate [41, 42] .
Mycophenolate Mofetil (MMF) showed superior prevention of acute rejection and better long term survival by reducing CAV compared to azathioprine when added to cyclosporine or tacrolimus [43, 44] . MMF seems to ameliorate the side effects of CNI of hyper- 
Diagnosis and treatment of acute cellular and humoral rejection
Acute cellular rejection (ACR) is a T cell mediated inflammatory response to the graft with infiltration of lymphocytes and macrophages. ACR can occur at any time after transplantation but most frequently during the first 3-6 months and is related to lapse in immunosuppressive therapy. Nearly 40% of adult heart transplant patients have one or more acute rejection episodes to some degree in the first month, about 60% experience rejection in 6 months and only one third remain free of rejection at 1 year after transplantation. Risk factors are younger age of recipient, female gender of donor and recipient, higher HLA mismatch, and black recipient.
ACR is a risk factor for CAV and mortality.
Diagnosis is made by EMB with the grading system proposed by Billingham initially in 1990 which was revised in 2004 (Table 3) [49]. Treatment is guided by clinical symptom, graft dysfunction and severity of ISHLT criteria on EMB. In asymptomatic patients with low grade ISHLT grade without graft dysfunction, augmentation of current immunosuppressive therapy or a course of steroid bolus can be given. In patients with graft dysfunction, intravenous pulse steroids are usually indicated to decrease the myocardial injury along with or without ATG (Table 5) . It is more commonly associated with hemodynamic compromise with graft dysfunction, increased graft loss, CAV and high mortality. It often presents in the first month after transplantation (Table 5 ).
There is no evidence based guidelines for the treatment of acute rejection in heart transplantation because of the lack of randomized controlled trials, thus, surveillance monitoring and treatment protocols for rejection remain largely empiric and vary among different transplant centers.
Cardiac allograft vasculopathy as chronic allograft rejection
CAV is an important chronic complication limiting long term graft survival which is mediated by predominantly immunologic mechanism, but shares major risk factors with conventional ath- 
CONCLUSION
Heart transplantation is the final option that can offer long term survival benefit in refractory end stage heart failure patients in this era. Advancement of immunology, sensitive and specific immune monitoring technology, refined and targeted immunosuppressive drugs, advancement in the management of complications and mechanical assist devices for the rescue therapy contributed to these achievements. Appropriate patient selection and individualized immunosuppression is the key to the successful outcome in heart transplantation.
Donor shortage is the major limitation of heart transplantation.
However, there are ongoing efforts to improve donor heart allocation and graft preservation. Moreover, technical advancement enabled LVAD to be implanted in replacement of for destination therapy in transplantation ineligible patients and offered LVAD as a bridge to transplantation for the morbid candidates in the waiting list. It has improved survival benefit compared to medical treatment alone but device associated complications and cost limits its widespread application. Further refinement in technology of mechanical assist device is necessary to overcome the barriers in the future. There has been steady increase in heart transplantations in Korea but candidates in waiting lists are increasing even faster. The short and long term survival is comparable to the survival of ISHLT and widespread application of mechanical assist device in heart failure is expected to happen in the very near future.
